Abstract
Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up season
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have